08:00 , Dec 24, 2007 |  BioCentury  |  Finance

Ebb & Flow

GlaxoSmithKline (LSE:GSK; GSK) lost £1.27 billion ($2.6 billion) in market cap Monday on news that FDA's Center for Biologics Evaluation and Research had issued a complete response letter for the company's Cervarix HPV vaccine. The disclosure...
08:00 , Dec 17, 2007 |  BC Week In Review  |  Company News

Anesiva, Medical Futures Inc. sales and marketing update

ANSV granted Medical Futures exclusive rights to market and distribute Zingo in Canada. ANSV will receive an undisclosed upfront payment and be paid a fixed transfer price. Medical Futures will be responsible for all the...
07:00 , Oct 22, 2007 |  BC Week In Review  |  Company News

Anesiva, Fosun Pharmaceutical Co. Ltd. deal

ANSV and Fosun's Jiangsu Wanbang Biological Pharmaceutical Corp. Ltd. unit formed a JV to manufacture Zingo. The needle-free injection of lidocaine powder was approved by FDA in August to treat pain associated with venous access...
07:00 , Aug 20, 2007 |  BC Week In Review  |  Clinical News

Zingo regulatory update

FDA approved an NDA from ANSV for Zingo to treat pain associated with venous access procedures in children ages 3 to 18. The company will provide guidance next month on the timing of the launch...
23:11 , Aug 17, 2007 |  BC Extra  |  Top Story

FDA approves Anesiva's Zingo

FDA approved an NDA for Zingo from ANSV to treat pain associated with venous access procedures in children ages three to 18. ANSV said it plans to submit an sNDA for the needle-free injection of...
08:00 , Feb 12, 2007 |  BC Week In Review  |  Clinical News

Zingo regulatory update

FDA accepted for filing an NDA for Zingo (3268) to treat pain associated with venous access procedures in children. The NDA was submitted on Nov. 22, 2006, and will be subject to a standard 10-month...
08:00 , Feb 12, 2007 |  BioCentury  |  Finance

Ebb & Flow

The hallway chatter at any financial or business development meeting these days is that M&A is the way to go and the markets are cold. Some wags even suggest there’s something wrong with any company...
02:04 , Feb 8, 2007 |  BC Extra  |  Company News

FDA accepts Zingo NDA

FDA accepted for filing an NDA from Anesiva (ANSV) for Zingo (3268) to treat pain associated with venous access procedures in children. The NDA was submitted on Nov. 22 and will receive a standard 10-month...
08:00 , Dec 4, 2006 |  BC Week In Review  |  Clinical News

Zingo regulatory update

ANSV submitted an NDA to FDA for Zingo to treat pain associated with venous access procedures in children. ANSV acquired the needle-free injection of lidocaine powder through its merger with AlgoRx last year. Anesiva Inc....
08:00 , Dec 4, 2006 |  BioCentury  |  Finance

Ebb & Flow

ConjuChem (TSX:CJB) recently disclosed positive Phase I/II data for PC-DAC: Exendin-4, a once-weekly therapeutic to treat diabetes. But the company was in a bind. It only had C$19 million ($16.7 million) in cash at July...